| 5.84 -0.06 (-1.02%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.28 | 1-year : | 8.51 |
| Resists | First : | 6.23 | Second : | 7.28 |
| Pivot price | 5.77 |
|||
| Supports | First : | 5.12  |
Second : | 4.44 |
| MAs | MA(5) : | 5.91 |
MA(20) : | 5.67 |
| MA(100) : | 5.53 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 67.3 |
D(3) : | 72.8 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 7.36 | Low : | 2.41 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLDB ] has closed below upper band by 41.3%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.98 - 6.01 | 6.01 - 6.03 |
| Low: | 5.69 - 5.72 | 5.72 - 5.75 |
| Close: | 5.79 - 5.84 | 5.84 - 5.88 |
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Tue, 16 Dec 2025
Solid Biosciences Supports Duchenne Muscular Dystrophy Inclusion in U.S. Newborn Screening Recommendations - Quiver Quantitative
Sat, 13 Dec 2025
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sat, 06 Dec 2025
Solid Biosciences (NASDAQ:SLDB) Coverage Initiated at Needham & Company LLC - MarketBeat
Thu, 04 Dec 2025
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst - Sahm
Mon, 17 Nov 2025
Solid Biosciences stock rises after licensing next-generation capsid - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 105.4 (%) |
| Shares Short | 10,540 (K) |
| Shares Short P.Month | 8,920 (K) |
| EPS | -2.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.79 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.7 % |
| Return on Equity (ttm) | -86.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -2.36 |
| PEG Ratio | 0 |
| Price to Book value | 2.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|